Purpose Campylobacter is a frequent cause of enteric infections with common antimicrobial resistance issues. The most recent reports of campylobacteriosis in Italy include data from 2013 to 2016. We aimed to provide national epidemiological and microbiological data on human Campylobacter infections in Italy during the period 2017–2021. Methods Data was collected from 19 Hospitals in 13 Italian Regions. Bacterial identification was performed by mass spectrometry. Antibiograms were determined with Etest or Kirby-Bauer (EUCAST criteria). Results In total, 5419 isolations of Campylobacter spp. were performed. The most common species were C. jejuni (n = 4535, 83.7%), followed by C. coli (n = 732, 13.5%) and C. fetus (n = 34, 0.6%). The mean age of patients was 34.61 years and 57.1% were males. Outpatients accounted for 54% of the cases detected. Campylobacter were isolated from faeces in 97.3% of cases and in 2.7% from blood. C. fetus was mostly isolated from blood (88.2% of cases). We tested for antimicrobial susceptibility 4627 isolates (85.4%). Resistance to ciprofloxacin and tetracyclines was 75.5% and 54.8%, respectively; resistance to erythromycin was 4.8%; clarithromycin 2% and azithromycin 2%. 50% of C. jejuni and C. coli were resistant to ≥ 2 antibiotics. Over the study period, resistance to ciprofloxacin and tetracyclines significantly decreased (p < 0.005), while resistance to macrolides remained stable. Conclusion Campylobacter resistance to fluoroquinolones and tetracyclines in Italy is decreasing but is still high, while macrolides retain good activity.

Zerbato, V., Di Bella, S., Pol, R., Luzzati, R., Sanson, G., Ambretti, S., Andreoni, S., Aschbacher, R., Bernardo, M., Bielli, A., Brigante, G., Busetti, M., Camarlinghi, G., Carcione, D., Carducci, A., Clementi, N., Carretto, E., Chilleri, C., Codda, G., Consonni, A., Costantino, V., Cortazzo, V., Di Santolo, M., Dodaro, S., Fiori, B., García-Fernández, A., Foschi, C., Gobbato, E., Greco, F., Marcello La Ragione, R., Mancini, N., Enrico Maraolo, A., Marchese, A., Marcuccio, D., Marrollo, R., Mauri, C., Mazzariol, A., Morroni, G., Mosca, A., Elisabetta Pagani, G. N., Maria Parisio, E., Pollini, S., Sarti, M., Sorrentino, A., Trotta, D., Villa, L., Vismara, C., Principe, L., Human Campylobacter spp. infections in Italy, <<European Journal of Clinical Microbiology & Infectious Diseases>>, 2024; 2024 (43): 895-904. [doi:10.1007/s10096-024-04803-0] [https://hdl.handle.net/10807/279596]

Human Campylobacter spp. infections in Italy

Fiori, Barbara;
2024

Abstract

Purpose Campylobacter is a frequent cause of enteric infections with common antimicrobial resistance issues. The most recent reports of campylobacteriosis in Italy include data from 2013 to 2016. We aimed to provide national epidemiological and microbiological data on human Campylobacter infections in Italy during the period 2017–2021. Methods Data was collected from 19 Hospitals in 13 Italian Regions. Bacterial identification was performed by mass spectrometry. Antibiograms were determined with Etest or Kirby-Bauer (EUCAST criteria). Results In total, 5419 isolations of Campylobacter spp. were performed. The most common species were C. jejuni (n = 4535, 83.7%), followed by C. coli (n = 732, 13.5%) and C. fetus (n = 34, 0.6%). The mean age of patients was 34.61 years and 57.1% were males. Outpatients accounted for 54% of the cases detected. Campylobacter were isolated from faeces in 97.3% of cases and in 2.7% from blood. C. fetus was mostly isolated from blood (88.2% of cases). We tested for antimicrobial susceptibility 4627 isolates (85.4%). Resistance to ciprofloxacin and tetracyclines was 75.5% and 54.8%, respectively; resistance to erythromycin was 4.8%; clarithromycin 2% and azithromycin 2%. 50% of C. jejuni and C. coli were resistant to ≥ 2 antibiotics. Over the study period, resistance to ciprofloxacin and tetracyclines significantly decreased (p < 0.005), while resistance to macrolides remained stable. Conclusion Campylobacter resistance to fluoroquinolones and tetracyclines in Italy is decreasing but is still high, while macrolides retain good activity.
2024
Inglese
Zerbato, V., Di Bella, S., Pol, R., Luzzati, R., Sanson, G., Ambretti, S., Andreoni, S., Aschbacher, R., Bernardo, M., Bielli, A., Brigante, G., Busetti, M., Camarlinghi, G., Carcione, D., Carducci, A., Clementi, N., Carretto, E., Chilleri, C., Codda, G., Consonni, A., Costantino, V., Cortazzo, V., Di Santolo, M., Dodaro, S., Fiori, B., García-Fernández, A., Foschi, C., Gobbato, E., Greco, F., Marcello La Ragione, R., Mancini, N., Enrico Maraolo, A., Marchese, A., Marcuccio, D., Marrollo, R., Mauri, C., Mazzariol, A., Morroni, G., Mosca, A., Elisabetta Pagani, G. N., Maria Parisio, E., Pollini, S., Sarti, M., Sorrentino, A., Trotta, D., Villa, L., Vismara, C., Principe, L., Human Campylobacter spp. infections in Italy, <<European Journal of Clinical Microbiology & Infectious Diseases>>, 2024; 2024 (43): 895-904. [doi:10.1007/s10096-024-04803-0] [https://hdl.handle.net/10807/279596]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/279596
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact